 |
| Ligand ID: GAI Drugbank ID: DB00536(Guanidine) Indication:For the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. |
| DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
|---|---|---|---|---|---|---|---|---|---|---|
 Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.36A | 19.19 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.37A | 19.19 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.37A | 19.19 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.34A | 19.19 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6lu7 | MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.35A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.54A | 22.56 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.56A | 22.56 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.53A | 22.56 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.55A | 22.56 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.54A | 22.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.55A | 22.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.53A | 22.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.55A | 22.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG C 131GLU C 288LEU C 286ASP C 289 | 1.80A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ASP B 289ARG B 131GLU B 288LEU B 286 | 1.42A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.53A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.54A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.56A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ASP C 289ARG C 131GLU C 288LEU C 286 | 1.80A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.55A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG B 131GLU B 288LEU B 286ASP B 289 | 1.45A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG B 131GLU B 288LEU B 286ASP B 289 | 1.44A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG B 131GLU B 288LEU B 286ASP B 289 | 1.44A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.35A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.35A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.34A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.33A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.59A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.60A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.61A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.58A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.68A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.69A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.66A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.69A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.57A | 18.86 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.58A | 18.86 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.55A | 18.86 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.54A | 18.86 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.43A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.40A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.43A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.42A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.39A | 22.36 | NoneNonePEG A 404 ( 3.6A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.38A | 22.36 | NoneNonePEG A 404 ( 3.6A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.38A | 22.36 | NoneNonePEG A 404 ( 3.6A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.36A | 22.36 | NoneNoneNonePEG A 404 ( 3.6A) | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.58A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.56A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.59A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.57A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_C_GAIC409_0 (PROTEIN (ARGINASE)) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | ASP A 289ARG A 131GLU A 288LEU A 286 | 1.52A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_A_GAIA407_0 (PROTEIN (ARGINASE)) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.55A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_F_GAIF411_0 (PROTEIN (ARGINASE)) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.53A | 22.36 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4CEV_D_GAID410_0 (PROTEIN (ARGINASE)) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | ARG A 131GLU A 288LEU A 286ASP A 289 | 1.55A | 22.36 | None |